This article explains Lu-177 PSMA therapy for metastatic castration-resistant prostate cancer (mCRPC). If your prostate cancer has spread, no longer responds to hormone therapy, and you're exploring what's next - or your doctor has mentioned Lu-177 PSMA as an option - this guide is for you.
How does Lu-177 PSMA therapy work?
Lu-177 PSMA therapy is a form of targeted radiation treatment. A small molecule called a ligand attaches to a radioactive atom called lutetium-177. This molecule finds and binds to a protein called PSMA on the surface of most prostate cancer cells. Once attached, it delivers radiation from right beside the cancer cell. The radiation kills or slows those cells while leaving most nearby healthy tissue unaffected.
In plain terms: the treatment finds the cancer, sticks to it, and irradiates it from the inside.
The full medical name is lutetium Lu-177 vipivotide tetraxetan. The brand name is Pluvicto. The FDA approved it in March 2022 for adults with PSMA-positive mCRPC who had already received an androgen receptor pathway inhibitor and a taxane chemotherapy regimen. See the FDA Approval Summary published in Clinical Cancer Research for more details.
What is PSMA - and why does it make a useful target?
PSMA stands for prostate-specific membrane antigen - a protein on the outer surface of prostate cancer cells. Most prostate cancers produce much more PSMA than healthy prostate tissue. This makes PSMA a useful target - the cancer cells show the exact protein the treatment looks for.
Not every prostate cancer shows enough PSMA for therapy to work. That's why you need a PSMA-PET scan - a specialized imaging test - before treatment starts. A doctor injects a small amount of radioactive tracer and takes images. The scan shows which tumour sites have PSMA and how much. If you have enough PSMA, you may qualify for Lu-177 PSMA therapy. If PSMA levels are low or absent, the therapy likely won't work, and your team will look at other options.
For a closer look at what PSMA-PET results mean and how eligibility is assessed, see How to Read Your PSMA PET Scan: A Patient Guide to Understanding Your Imaging and Your Lu-177 Eligibility.
What is theranostics - and how does it apply to prostate cancer?
Theranostics combines "therapy" and "diagnostics." It means using the same target - PSMA in this case - both to find the cancer and treat it. The diagnostic tool and the therapy use the same principle. That's what makes it a theranostic pair.
Here's how theranostics works for prostate cancer:
- A diagnostic tracer - such as gallium-68 gozetotide, commonly called a gallium-68 PSMA scan - is injected and a PET/CT scan is taken. The scan shows where PSMA is present in the body and how much each tumour site expresses.
- If you have enough PSMA in your cancer sites, your doctor gives you a therapeutic agent - lutetium Lu-177 vipivotide tetraxetan. It carries lutetium-177 to the same PSMA targets that showed up on the diagnostic scan.
- Lutetium-177 gives off beta particles (a type of radiation) that travel only about 2 to 3 millimetres in human tissue. This short range means the radiation reaches nearby cancer cells but doesn't travel far into healthy tissue.
The diagnostic scan and the therapy use the same targeting logic. You can see what will be treated before you start. This is what makes theranostics precise - imaging shows the target, and therapy hits the same spots.
How does lutetium-177 actually damage cancer cells?
When the ligand in lutetium Lu-177 vipivotide tetraxetan binds to PSMA, the lutetium-177 sits right beside the cancer cell. The beta radiation damages the DNA inside and around that cell. This is called the "crossfire effect" - cancer cells next to the targeted one also get radiation from nearby bound molecules.
DNA damage stops the cell from dividing correctly. Often the cell dies. This works like external-beam radiation, except it comes from inside the body, targeting cancer directly instead of passing through healthy tissue first.
Because radiation travels only a short distance, tissues without much PSMA get much lower doses than PSMA-positive cancer cells. This makes the therapy more targeted, though it doesn't prevent all side effects.
What does a course of Lu-177 PSMA treatment actually involve?
In the VISION trial - the main study that led to FDA approval - patients received lutetium Lu-177 vipivotide tetraxetan at 7.4 gigabecquerels (GBq) through an IV line once every six weeks, for up to six cycles. Each infusion takes place in a specialized nuclear medicine center and usually takes 20 to 30 minutes.
After each infusion, the lutetium-177 in your body breaks down naturally over the next few days. During this time, follow basic precautions to limit radiation exposure to others - especially children and pregnant women. Your care team will give you specific written instructions before you go home. Most patients are discharged the same day as their infusion.
Between cycles, your doctor orders blood tests and imaging to check how your cancer is responding and whether your kidneys and bone marrow are healthy. Your doctor may pause or stop treatment if side effects are too much or if the cancer stops responding.
What did the VISION trial find?
The VISION trial included 831 men with PSMA-positive mCRPC who had already received at least one androgen receptor pathway inhibitor and at least one taxane-based chemotherapy. They were randomly assigned to receive lutetium Lu-177 vipivotide tetraxetan plus standard care, or standard care alone.
The results, published in the New England Journal of Medicine and confirmed in the FDA Approval Summary, showed:
- Radiographic progression-free survival (rPFS) - hazard ratio of 0.40, meaning the risk of imaging-confirmed disease progression or death dropped by about 60% in the treatment group compared to standard care alone.
- Overall survival - hazard ratio of 0.62, meaning the risk of death dropped by about 38% compared to standard care alone.
Both results were statistically significant. The Prostate Cancer Foundation has explained what this approval means for patients in clear language on its website.
These are average results from a controlled trial of hundreds of patients with the same disease profile. Individual results vary. Some men see PSA drop and less bone pain. Others don't respond the same way. Researchers are still learning who benefits most and why.
Who may be eligible for Lu-177 PSMA therapy?
Patients who may be considered for this therapy usually have these characteristics (based on VISION trial criteria and FDA approval):
- Confirmed metastatic castration-resistant prostate cancer
- PSMA-positive disease on a PSMA-PET scan - meaning most tumour sites show strong PSMA expression
- Prior treatment with at least one androgen receptor pathway inhibitor (such as enzalutamide or abiraterone)
- Prior treatment with at least one taxane chemotherapy regimen (such as docetaxel)
- Adequate kidney, bone marrow, and liver function at baseline
- No tumour sites that appear active on other imaging but PSMA-negative on the PET scan - which may suggest those areas have lost PSMA expression
Eligibility is not always straightforward. If your treatment path is different - for instance, if you couldn't handle chemotherapy or your PSMA-PET results are mixed - a specialist can help clarify your options. For a detailed look at how prior chemotherapy fits into eligibility decisions, see Lu-177 PSMA After Docetaxel: mCRPC Eligibility Guide.
If you're not sure whether you qualify, you can request a Lu-177 eligibility review through Art of Healing Cancer. Their team of nuclear medicine and cancer doctors experienced in radioligand therapy will review your imaging and help clarify your options.
What are the most common side effects?
For most patients in the VISION trial, lutetium Lu-177 vipivotide tetraxetan had manageable side effects. The most common side effects - happening in 20% or more of patients - were:
- Fatigue
- Dry mouth (xerostomia) - because salivary glands carry some PSMA receptors
- Nausea
- Anemia and related blood count changes
- Decreased appetite
- Constipation
Dry mouth is worth knowing about. The therapy can affect salivary glands because they have low levels of PSMA. Most patients describe mild to moderate dry mouth during and after their treatment cycles. Some centers use cooling or other protective measures around the salivary glands during infusion to reduce this, though practices differ.
Your doctor monitors blood counts between cycles because the therapy can affect bone marrow. This matters more if you have a lot of bone disease. Your doctor also checks kidney function throughout treatment.
How does Lu-177 PSMA differ from chemotherapy and external radiation?
Chemotherapy circulates through the whole body and stops all fast-dividing cells - which is why it can cause hair loss, nausea, and low immunity. It doesn't target any specific protein. It affects dividing cancer cells and healthy cells alike.
External-beam radiation targets a specific area from outside the body. It works well for one or a few tumour sites, but not when cancer has spread widely.
Lu-177 PSMA therapy is systemic - it travels through the bloodstream and reaches all PSMA-positive tumours throughout the body in one course. But it's also targeted - it acts only on cells with PSMA, not on all fast-dividing cells. For men with cancer spread throughout bones and lymph nodes, this combination makes it a good option when standard treatments stop working.
Is Lu-177 PSMA available outside the US and Europe?
Access varies widely by country. The therapy is approved by the FDA in the United States and by the European Medicines Agency in Europe. In much of Africa, the Gulf region, and South and Southeast Asia, the therapy isn't available yet. Patients from these regions have gone to India for treatment, where accredited nuclear medicine centers offer it for international patients.
If access in your home country is limited, our guide on Lu-177 PSMA Therapy Not Available in Your Country? How International Patients Get Treatment in India covers what the journey looks like from initial eligibility review through to travel logistics and treatment cycles.
When to talk to your doctor
Consider raising Lu-177 PSMA therapy with your oncologist or a nuclear medicine specialist if:
- Your mCRPC has progressed despite androgen receptor pathway inhibitors and chemotherapy
- You have not yet had a PSMA-PET scan and want to know whether you qualify
- Your current team has not discussed Lu-177 PSMA therapy as a potential next step
- You are weighing this option against other treatments at your current stage
- You are considering travelling abroad to access this therapy
If you want an independent eligibility check or second opinion, you can send your scan reports and treatment history through the Lutetium Therapy contact form. If Lu-177 PSMA isn't right for you, the team can suggest other treatment options.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
What does PSMA stand for, and why is it such a good target for prostate cancer treatment?
PSMA stands for prostate-specific membrane antigen. It is a protein that sits on the outer surface of prostate cancer cells. Most prostate cancers produce far more PSMA than normal tissue does. This overexpression makes PSMA a reliable marker that the therapy can seek out and bind to, delivering radiation directly to cancer cells while reducing exposure to unaffected tissue elsewhere in the body.
Do I need a PSMA-PET scan before I can get Lu-177 PSMA therapy?
Yes. A PSMA-PET scan is required before treatment to confirm that your tumours express PSMA at levels high enough for the therapy to be effective. If PSMA expression is low or absent across your disease sites, the treatment is unlikely to work, and your care team will need to consider other options. The scan also helps identify any sites that may not respond because they have lost PSMA expression.
How many treatment cycles are given, and how far apart are they?
In the VISION trial - the study that supported regulatory approval in the United States - patients received up to six cycles of lutetium Lu-177 vipivotide tetraxetan, given once every six weeks. Blood tests and imaging are performed between cycles to assess both response and safety. Treatment may be paused or stopped earlier if it is no longer effective or if side effects require it.
Is Lu-177 PSMA therapy the same as chemotherapy?
No. Chemotherapy circulates through the entire body and disrupts all rapidly dividing cells, whether cancerous or healthy. Lu-177 PSMA therapy is targeted - it seeks out cancer cells that express the PSMA protein and delivers radiation directly to those cells. The side effect profiles are different. Lu-177 PSMA does not typically cause hair loss, for example, but it can cause dry mouth, fatigue, and blood count changes.
What happens if my PSMA-PET scan shows low or no PSMA expression?
If your PSMA-PET scan shows low or absent expression, you may not be eligible for Lu-177 PSMA therapy, because the treatment has no reliable target to bind to. This does not mean there are no other options available. Your oncologist can review other lines of therapy, and a second opinion from a specialist experienced in radioligand therapy can help clarify which alternative paths may be suitable for your specific case.